What is it about?
This study investigates the use of a medical device (plasma care® by terraplasma medical GmbH, Germany) which generates cold atmospheric plasma (CAP) as an innovative treatment for chronic wounds. The study compared CAP combined with standard care against placebo plus standard care in a heterogeneous patient cohort. The results show that CAP significantly accelerates wound healing, reduces wound size, and improves key clinical parameters including pH, pain, and exudate management. It could be shown that 54,3% of chronic wounds were completely closed in 6 weeks in the CAP group, compared to only 5.7% in the placebo group. Its safety and tolerability make it a compelling option for improving patient outcomes in wound care.
Featured Image
Photo by Kellen Barnes on Unsplash
Why is it important?
Chronic wounds pose a major health challenge, affecting patients’ quality of life and incurring high treatment costs. Despite existing therapies, many wounds heal slowly or not at all. This research highlights CAP as a promising therapy that can enhance healing, combat infections, and potentially reduce healthcare expenses. The findings support the growing interest in cold plasma-based therapies for medical applications. CAP’s ability to stimulate cellular regeneration, reduce bacterial load, and modify wound environments offers a multifaceted approach to wound management. As technology advances, CAP could become a standard component of comprehensive wound care, improving healing rates and patient quality of life worldwide.
Perspectives
This study represents a major milestone in the clinical application of cold atmospheric plasma for wound care. It is the first placebo-controlled trial using the plasma care® device with such a large patient cohort (70 patients), and the results are nothing short of remarkable: The significant improvements in wound healing, especially the complete closure of over half of the chronic wounds in just six weeks, clearly demonstrate the power of this technology. What makes this even more exciting is the excellent tolerability and safety profile of CAP therapy. These findings mean we now have strong clinical evidence that we can truly help patients with chronic wounds in a meaningful way. For many of these individuals, healing had stalled despite standard treatments. With CAP, we’re offering a scientifically validated, innovative solution that improves not only physical outcomes but potentially also patients’ quality of life and psychological well-being. This isn’t just another wound care option. It’s therefore a real breakthrough that brings us one step closer to setting a new standard in chronic wound treatment.
Lisa Gebhardt
terraplasma medical GmbH
Read the Original
This page is a summary of: Treatment of chronic wounds with cold plasma: a randomised, single-blind, placebo-controlled clinical study, Journal of Wound Care, July 2025, Mark Allen Group,
DOI: 10.12968/jowc.2025.0207.
You can read the full text:
Contributors
The following have contributed to this page
